Proteostasis Therapeutics , Inc. is a clinical stage biopharmaceutical company, which engages in the discovery and development of novel therapeutics to treat cystic fibrosis ( CF ), and other diseases caused by an imbalance in the proteostasis network. The company was founded by William Balch, Jeffery W. Kelly, Andrew Dillin, Richard I. Morimoto, Alfred Lewis Goldberg, Daniel Finley, Christopher T. Walsh, and Randall W. King in 2006 and is headquartered in Boston, MA.